Manhattan Scientifics Names V. Gerald Grafe to Commercialize Senior Scientific

Manhattan Scientifics (OTCBB: MHTX) today announced it has named V. Gerald Grafe to lead the commercialization of Senior Scientific. On June 6^th Manhattan Scientifics announced its acquisition of Senior Scientific LLC to commercialize the groundbreaking tools for cancer detection, diagnosis, and treatment originated by Dr. Edward R. Flynn Ph.D. The new nanotechnology tools can detect tumors and metastases much earlier than currently possible, and can measure and locate tumors more precisely than ever before. The technology can enable personalized and precise treatment since it can identify the exact type of cancer cells present, allowing doctors to design treatments for the exact type and extent of cancer present.

Mr. Grafe, 47, has focused his career on developing new technologies. He has served as legal counsel and advisor to over 100 early stage companies, with successes in strategic IP and patent planning, venture capital financing, and technology transfer with Sandia and Los Alamos labs and with the University of New Mexico. Under a consulting agreement, Mr. Grafe will serve as the President of Senior Scientific.

Manhattan CEO Manny Tsoupanarias said, "On June 6^th we announced the acquisition of Senior Scientific and its game-changing medical/cancer technology. The Senior Scientific technology has the potential to dramatically improve detection and treatment in a wide range of cancers, and I believe Gerald is the ideal person to integrate the many elements needed to realize that potential. He has exactly the experience bringing new and highly technical ideas to life that Senior Scientific needs: protection of intellectual property, strategic planning, financing, and strategic partner relationships. Our board and management are honored to have Gerald Grafe accept the presidency of Senior Scientific.”

Marvin Maslow, Manhattan Scientifics Founder said, "Gerald Grafe is the best man for the job. We are blessed to have him undertake this responsibility. Gerald Grafe brings us an impressive array of outstanding business, technical, medical and patent legal skills. He will drive our team to achieve our corporate goal: significant profit and creation of substantial shareholder value while we positively impact humanity by helping overcome the horrors of cancer, the emperor of all maladies.”

Mr. Grafe has served in private legal practice for the past decade as general counsel and intellectual property counsel for various venture-funded and public companies and New Mexico venture capitalist investors. He provided initial company strategic planning, U.S. and foreign intellectual property strategy and implementation, and counsel and management of license, financing, and strategic partner relationships. Clients include CVI, InLight Solutions, TruTouch Technologies, VeraLight, Luminous Medical, Novint Technologies, Manhattan Scientifics, ARS-USA, Vertical Power, Avanca, Aspen Avionics, and NASUS. Mr. Grafe has for many years been an advisor to early stage technology companies at TVC’s Equity Capital Symposium.

Before he began his work with startup companies, Mr. Grafe was an attorney in Sandia National Laboratories, where he worked as Intellectual Property legal counsel for divisions including robotics, computing, and systems. He helped define intellectual property mining and protection practices, filed and prosecuted a number of patents, developed technology transfer practices, and helped close many technology transfer transactions. Before moving to the legal department, he was a Senior Member of Technical Staff at Sandia National Laboratories, working on topics involving advanced electrical and computer technology, including: medical imaging, parallel computer architectures, network computing, embedded computing, and robotic vision.

Mr. Grafe holds a B.S. in Electrical Engineering from Texas A & M summa cum laude, an M.S. Electrical and Computer Engineering from the University of New Mexico, and earned his Juris Doctor summa cum laude from the University of New Mexico School of Law.

About Senior Scientific

Edward R. Flynn, Ph.D, founded Senior Scientific LLC (www.seniorscientific.com) to develop a nano-electromagnetic sensing technology, originally to detect breast cancer in women where mammograms were not effective. The technology has proven capable of measuring very small tumors – 100,000 cells, versus 100,000,000 or more required for conventional techniques i.e. the mammogram. It is applicable to a wide range of cancers, including breast, prostate, ovarian, pancreatic, brain, and others. It can detect initial tumors and subsequent metastases years earlier than current diagnostic techniques, and can provide precise treatment guidance that can reduce expensive and painful over-treatment. The technology uses magnetic nanoparticles combined with antibodies that target specific kinds of cancer cells. Special instrumentation precisely locates and accurately counts the number of cancer cells present based on the nanoparticles bound by antibodies to the cancer cells. The nanoparticles are nontoxic, and the instrumentation does not require radiation or strong magnetic fields. The system can be used for both diagnostics and targeted therapies. Manhattan Scientifics has applied for 24 patents to protect the inventions and three leading research hospital cancer centers in the U.S have expressed interest in collaborations with this technology.

About Manhattan Scientifics

Manhattan Scientifics Inc. (www.mhtx.com) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of disruptive technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.